Sarepta Therapeutics Inc (SRPT)

Precedente Chiudi:

$132.74

Aprire:

$132.88

Volume 24 ore:

844.90K

Capitalizzazione di mercato:

$12.42B

Reddito:

$1.40B

Utile/perdita netta:

$16.90M

Rapporto P/E:

-16.78

EPS:

-7.83

Flusso di cassa netto:

$-653.88M

1 W Prestazione:

-0.33%

1M Prestazione:

+11.44%

6M Prestazione:

+58.00%

1 anno Prestazione:

-11.69%

Intervallo 1D:

$129.50

$133.12

Portata 52W:

$55.25

$152.21

Sarepta Therapeutics Inc Stock (SRPT) Company Profile

Nome

Sarepta Therapeutics Inc

Settore

Healthcare (1209)

Industria

Biotechnology (699)

Telefono

617-274-4000

Indirizzo

215 First Street, Suite 415, Cambridge, MA

Dipendente

255

Cinguettio

@sarepta

Prossima data di guadagno

2024-06-06

Ultimi documenti SEC

SRPT's Discussions on Twitter

Sarepta Therapeutics Inc Stock (SRPT) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2024-01-31	Iniziato	BMO Capital Markets	Outperform
2023-12-13	Ripresa	Citigroup	Buy
2023-12-12	Iniziato	Deutsche Bank	Buy
2023-11-21	Iniziato	Wedbush	Outperform
2023-10-31	Downgrade	Cantor Fitzgerald	Overweight → Neutral
2023-10-31	Downgrade	Oppenheimer	Outperform → Perform
2023-06-23	Downgrade	Evercore ISI	Outperform → In-line
2023-04-26	Iniziato	SMBC Nikko	Outperform
2023-04-04	Iniziato	Citigroup	Buy
2023-03-01	Aggiornamento	Morgan Stanley	Equal-Weight → Overweight
2022-12-22	Reiterato	BTIG Research	Buy
2022-12-16	Aggiornamento	UBS	Neutral → Buy
2022-04-04	Ripresa	Cantor Fitzgerald	Overweight
2022-01-05	Reiterato	Needham	Buy
2021-12-09	Aggiornamento	Oppenheimer	Perform → Outperform
2021-11-05	Aggiornamento	JP Morgan	Neutral → Overweight
2021-09-15	Aggiornamento	Guggenheim	Neutral → Buy
2021-08-05	Aggiornamento	JP Morgan	Underweight → Neutral
2021-06-15	Iniziato	BTIG Research	Buy
2021-04-26	Ripresa	Credit Suisse	Neutral
2021-01-12	Downgrade	Citigroup	Buy → Neutral
2021-01-11	Downgrade	UBS	Buy → Neutral
2021-01-08	Downgrade	JP Morgan	Overweight → Underweight
2021-01-08	Downgrade	Morgan Stanley	Overweight → Equal-Weight
2021-01-08	Downgrade	Raymond James	Outperform → Mkt Perform
2020-11-11	Iniziato	Berenberg	Hold
2020-10-28	Iniziato	UBS	Buy
2020-08-25	Iniziato	Raymond James	Outperform
2020-08-20	Downgrade	Credit Suisse	Outperform → Neutral
2020-03-31	Iniziato	Mizuho	Buy
2019-11-01	Iniziato	Guggenheim	Buy
2019-08-21	Reiterato	Needham	Buy
2019-07-09	Reiterato	Morgan Stanley	Overweight
2019-07-01	Reiterato	RBC Capital Mkts	Outperform
2019-04-12	Iniziato	Evercore ISI	Outperform
2019-03-11	Reiterato	Credit Suisse	Outperform
2018-10-12	Iniziato	Bernstein	Outperform
2018-10-01	Iniziato	Cantor Fitzgerald	Overweight
2018-09-26	Reiterato	RBC Capital Mkts	Outperform
2018-09-14	Ripresa	BofA/Merrill	Buy
2018-09-06	Iniziato	Credit Suisse	Outperform
2018-08-01	Aggiornamento	Morgan Stanley	Equal-Weight → Overweight
2018-06-21	Reiterato	Robert W. Baird	Outperform
2018-06-20	Reiterato	Needham	Buy
2018-06-19	Reiterato	H.C. Wainwright	Buy

Mostra tutto

Sarepta Therapeutics Inc Borsa (SRPT) Ultime notizie

Thornburg Investment Management Inc. Buys 23,406 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat

MarketBeat

Sarepta Therapeutics (NASDAQ:SRPT) PT Raised to $179.00 - MarketBeat

MarketBeat

Sarepta hopeful on Elevidys label expansion - MSN

MSN

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Sold by Fiera Capital Corp - MarketBeat

MarketBeat

International Assets Investment Management LLC Acquires 11259 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - Defense World

Defense World

Sarepta says adverse event report for DMD gene therapy erroneously submitted - Yahoo Movies UK

Yahoo Movies UK

Sarepta Therapeutics Inc Azioni (SRPT) Dati Finanziari

Sarepta Therapeutics Inc (SRPT) Reddito 2024

Sarepta Therapeutics Inc (SRPT) Reddito netto 2024

Sarepta Therapeutics Inc (SRPT) Flusso di cassa 2024

Sarepta Therapeutics Inc (SRPT) Utile per azione 2024

Sarepta Therapeutics Inc Azioni (SRPT) insider trading